Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus ANORO ELLIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus ANORO ELLIPTA.
ADVAIR DISKUS 100/50 vs ANORO ELLIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing cAMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
ANORO ELLIPTA is a combination of umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). Umeclidinium inhibits acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation. Vilanterol stimulates beta2-adrenergic receptors, leading to relaxation of bronchial smooth muscle and increased cyclic AMP.
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
One inhalation (umeclidinium 62.5 mcg / vilanterol 25 mcg) once daily, orally inhaled.
None Documented
None Documented
Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing.
Umeclidinium: 11 hours (terminal); vilanterol: 2.5 hours (terminal). Steady-state achieved by day 14 once-daily dosing.
Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination.
Umeclidinium: 0.7% unchanged in urine, 58% as metabolites in feces; vilanterol: 26% unchanged in urine, 70% as metabolites in feces. Total elimination: renal (30-40% for vilanterol metabolites) and fecal (primary).
Category C
Category C
Corticosteroid/LABA Combination
LAMA/LABA Combination